Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients

Melanoma Research

Volumn 18, Issue 3, 2008, Pages 220-224

  Voelter, Verena ^a,d   Schalenbourg, Ann ^a   Pampallona, Sandro ^b   Peters, Solange ^a   Halkic, Nermin ^a   Denys, Alban ^a   Goitein, Gudrun ^c   Zografos, Leonidas ^a   Leyvraz, Serge ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b ForMed   (Switzerland)

^c PAUL SCHERRER INSTITUTE   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Adjuvant chemotherapy; Intra arterial hepatic fotemustine; Liver metastases; Uveal melanoma

Indexed keywords

FOTEMUSTINE; METHYLPREDNISOLONE; ONDANSETRON;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHOLANGITIS; CLINICAL ARTICLE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; LIVER NECROSIS; LIVER TOXICITY; MALE; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTON THERAPY; SIDE EFFECT; STOMACH INJURY; THROMBOCYTOPENIA; TOXIC HEPATITIS; TREATMENT OUTCOME; UVEA MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; RECURRENCE; RISK; SURVIVAL ANALYSIS; UVEAL NEOPLASMS;

EID: 43649087573     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32830317de     Document Type: Article

References (25)

1. Hakulinen T, Teppo L, Saxen E. Cancer of the eye, a review of trends and differentials. World Health Stat Q 1978; 31:143-158.
2. Osterlind A. Trends in incidence of ocular malignant melanoma in Denmark 1943-1982. Int J Cancer 1987; 40:161-164.
3. Scotto J, Fraumeni JF Jr, Lee JA. Melanomas of the eye and other noncutaneous sites: epidemiologic aspects. J Natl Cancer Inst 1976; 56:489-491.
4. COMS. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 2001; 119:670-676.
5. Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol 1992; 110:245-250.
6. McLean IW, Foster WD, Zimmerman LE. Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol 1982; 13:123-132.
7. Shields CL, Shields JA, Kiratli H, De Potter P, Cater JR. Risk factors for growth and metastasis of small choroidal melanocytic lesions. Ophthalmology 1995; 102:1351-1361.
8. Zografos L. Tumeurs intraoculaires. Paris: Société FranÇaise d'Ophtalmologie et Masson; 2002.
9. Bedikian AY, Kantarjian H, Young SE, Bodey GP. Prognosis in metastatic choroidal melanoma. South Med J 1981; 74:574-577.
10. Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, Finn SM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology 1991; 98:383-389; discussion 390.
11. Kath R, Hayungs J, Bornfeld N, Sauerwein W, Hoffken K, Seeber S. Prognosis and treatment of disseminated uveal melanoma. Cancer 1993; 72:2219-2223.
12. Albert DM, Niffenegger AS, Willson JK. Treatment of metastatic uveal melanoma: review and recommendations. Surv Ophthalmol 1992; 36:429-438.
13. Becker JC, Terheyden P, Kampgen E,Wagner S, Neumann C, Schadendorf D, et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer 2002; 87:840-845.
14. Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M.D. Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76:1665-1670.
15. Leyvraz S, Spataro V, Bauer J, Pampallona S, Salmon R, Dorval T, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997; 15:2589-2595.
16. Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, Gillet M, et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 2006; 17:578-583.
17. Sanborn G, Niederkorn J, Kan-Mitchell J, Albert D. Prevention of metastasis of intraocular melanoma in mice treated with difluoromethylornithine. Graefes Arch Clin Exp Ophthalmol 1992a; 230:72-77.
18. Sanborn GE, Niederkorn JY, Gamel JW. Efficacy of dacarbazine (DTIC) in preventing metastases arising from intraocular melanomas in mice. Graefes Arch Clin Exp Ophthalmol 1992b; 230:192-196.
19. Herrmann KA, Waggershauser T, Sittek H, Reiser MF. Liver intraarterial chemotherapy: use of the femoral artery for percutaneous implantation of catheter-port systems. Radiology 2000; 215:294-299.
20. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
21. Zimmerman LE, McLean IW, Foster WD. Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells. Br J Ophthalmol 1978; 62:420-425.
22. Desjardins L, Dorval T, Lévy C, Cojean I, Schlienger P, Slamon R, et al. Randomized study of adjuvant therapy by DTIc in choroidal melanoma. Ophthalmologie 1998; 12:168-173.
23. Gragoudas ES, Lane AM, Munzenrider J, Egan KM, Li W. Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma. Trans Am Ophthalmol Soc 2002; 100:43-48; discussion 48-49.
24. Egger E, Zografos L, Schalenbourg A, Beati D, Bohringer T, Chamot L, Goitein G. Eye retention after proton beam radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys 2003; 55:867-880.
25. Egger E, Schalenbourg A, Zografos L, Bercher L, Boehringer T, Chamot L, Goitein G. Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma. Int J Radiat Oncol Biol Phys 2001; 51:138-147.